MEHMET BİLGEHAN PEKTAŞ, Mustafa ALDEMİR, AYHAN PEKTAŞ, Önder AKÇİ, İsmet DOĞAN

Would Anti-Hypertensive Treatment be a Risk Factor for National Health Budget of Turkey in 2023?

This study aims to predict the prevalence of hypertension and the cost of anti-hypertensive treatment in future by analyzing the adults diagnosed with hypertension and the drugs prescribed for their treatment in Turkey during a period of five years. This study reviews data related to the patients diagnosed with hypertension amongst the individuals registered within the Medula database of the Turkish Social Insurance Institution from 2009 to 2013. A significant and gradual increase was specified in the prevalence of hypertension during the study period. The number of female patients was significantly higher than the number of male patients over the passing years. The number of anti-hypertensive drug boxes consumed was significantly increased during the study period. Surprisingly, the number of anti-hypertensive boxes annually consumed by the hypertensive patients remained statistically similar between 2009 and 2013. A significant increase was noted in the prescription of angiotensin II receptor blockers, beta blockers, and angiotensin converting enzyme inhibitors during the study period. The cost of anti-hypertensive treatment was found to decrease by 36.7% during the study period. The economical measures currently adopted for drug pricing are successful but health policies developed for the prevention of hypertension are inadequate.

PDF

___

1. Tamosiunas A, Luksiene D, Baceviciene M, Bernotiene G, Radisauskas R, Malinauskiene V, Kranciukaite-Butylkiniene D, Virviciute D, Peasey A, Bobak M. Health Factors and Risk of All-Cause, Cardiovascular, and Coronary Heart Disease Mortality: Findings from the MONICA and HAPIEE Studies in Lithuania. PLoS One. 2014;9(12):e114283.

2. De Miguel C, Rudemiller NP, Abais JM, Mattson DL. Inflammation and hypertension: new understandings and potential therapeutic targets. Curr Hypertens Rep 2015;17(1):507.

3. Malyszko J, Bachorzewska-Gajewska H, Dobrzycki S. Renalase, kidny and cardiovascular disease: Are they related or just coincidentally associated? Adv Med Sci. 2014;60(1):41-9.

4. Hamano T, Kimura Y, Takeda M, Yamasaki M, Isomura M, Nabika T, Shiwaku K. Effect of environmental and lifestyle factors on hypertension: Shimane COHRE study. PLoS One. 2012;7(11): e49122.

5. Sengul S, Erdem Y, Akpolat T, Derici U, Sindel S, Karatan O, Turgan C, Hasanoglu E, Caglar S, Erturk S. Controlling hypertension in Turkey: not a hopeless dream. Kidney Int Suppl. 2013;3(4):326-31.

6. Altun B, Süleymanlar G, Utaş C, Arınsoy T, Ateş K, Ecder T, Camsarı T, Serdengeçti K. Prevalence, awareness, treatment and control of hypertension in adults with chronic kidney disease in Turkey: results from the CREDIT study. Kidney Blood Press Res. 2012;36(1):36-46.

7. Akici A, Kalaça S, Uğurlu U, Toklu HZ, Oktay S. Antihypertensive drug utilization at health centres in a district of Istanbul. Pharm World Sci. 2007;29(3):116-21.

8. Tatar M, Mollahaliloğlu S, Sahin B, Aydin S, Maresso A, Hernández-Quevedo C. Turkey. Health system review. Health Syst Transit. 2011;13(6):1-186, xiii-xiv.

9. Abramson BL, Melvin RG. Cardiovascular risk in women: focus on hypertension. Can J Cardiol. 2014;30(5):553-9.

10. Cengel A. Cardiovascular risk factors in women. Turk Kardiyol Dern Ars. 2010;38Suppl 1:17-24.

11. Kitiş Y, Bilgili N, Hisar F, Ayaz S. Frequency and affecting factors of metabolic syndrome in women older than 20 years of age. Anadolu Kardiyol Derg. 2010;10(2):111-9.

12. Gür Ali O, Topaler B.How removing prescription drugs from reimbursement lists increases the pharmaceutical expenditures for alternatives. Eur J Health Econ. 2011;12(6):553-62.

13. Ide H, Mollahaliloglu S. How firms set prices for medical materials: a multi-country study. Health Policy. 2009;92(1):73-8.

14. Kent ST, Shimbo D, Huang L, Diaz KM, Kilgore ML, Oparil S, Muntner P. Antihypertensive medication classes used among medicare beneficiaries initiating treatment in 2007-2010. PLoS One. 2014;9(8):e105888.

15. Christe V, Waeber G, Vollenweider P, Marques-Vidal P. Antihypertensive drug treatment changes in the general population: the CoLaus study. BMC Pharmacol Toxicol. 2014;15(1):20.

16. Abaci A, Kozan O, Oguz A, Sahin M, Deger N, Senocak H, Toprak N, Sur H, Erol C. Prescribing pattern of antihypertensive drugs in primary care units in Turkey: results from the TURKSAHA study. Eur J Clin Pharmacol. 2007;63(4):397-402.